H.C. Wainwright raised the firm’s price target on Mineralys Therapeutics (MLYS) to $52 from $42 and keeps a Buy rating on the shares. The firm says its key onion leader conversations on the unmet need for resistant and uncontrolled hypertension patients is “supportive” of lorundrostat’s profile in uncontrolled and resistant hypertension.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics completes enrollment in Phase 2 EXPLORE-OSA trial
- Insiders Pour Millions into These 2 Stocks — Goldman Sachs Backs the Move
- Mineralys Therapeutics falls -4.9%
- Mineralys Therapeutics price target raised to $50 from $26 at Wells Fargo
- Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial Position